Biotech Values

[DewDiligence]

GILD’s Simtuzumab failed to increase PFS as an addend to Gemzar in a phase-2 trial in first-line pancreatic cancer:

http://finance.yahoo.com/news/gilead-announces-data-phase-2-100000449.html

“Although simtuzumab did not provide clinical benefit in difficult-to-treat advanced pancreatic cancer patients in this study, we continue to explore simtuzumab in other areas of unmet medical need, with ongoing clinical trials in colorectal cancer, myelofibrosis and serious fibrotic lung and liver diseases,” said Norbert Bischofberger, PhD, Gilead’s Executive Vice President of Research and Development and Chief Scientific Officer.

GILD picked up Simtuzumab (f/k/a/ GS-6624) in the 2010 acquisition of Arresto Biosciences (#msg-57962898).